SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis.

What the trial testedas reported · 2024

Not counted

+31%+10% to +55%

Bigger than 7 in 10 for all-cause mortality

As reported

HR 1.308, 95% CI 1.10–1.55 · the paper's word: All-cause mortality

the abstract, start to end

… higher all-cause mortality (hazard ratio 1.308, 95% confidence interval …

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 1.3081.10–1.55

MetforminSGLT2 inhibitorsAll-cause mortality

1 / 3

2024

2025

2026

this papercites it